Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. surgical resection
Show results for
Products
Services
Applications

Companies

News
Articles
Downloads
Videos

Refine by
Date

  • Older

Surgical Resection Articles & Analysis

16 news found

SEngine Precision Medicine Partners with Vincere Cancer Center to Increase Access for First Responders to Get Personalized Cancer Treatments via the PARIS Test

SEngine Precision Medicine Partners with Vincere Cancer Center to Increase Access for First Responders to Get Personalized Cancer Treatments via the PARIS Test

A patient’s tumor biopsy or surgical resection will be generated at Vincere and then sent to SEngine’s laboratory in Seattle, where up to 44 drugs from a library of over 240 options will be tested on the tumor model through the PARIS Test. ...

BySEngine Precision Medicine


Aesther Healthcare Acquisition Corp. Has Entered Into an Agreement and Plan of Merger with Ocean Biomedical, Inc., a Next-Generation Biopharma Company, to List on NASDAQ

Aesther Healthcare Acquisition Corp. Has Entered Into an Agreement and Plan of Merger with Ocean Biomedical, Inc., a Next-Generation Biopharma Company, to List on NASDAQ

Currently, NSCLC is primarily being treated by surgical resection with curative intent, although radiation and chemotherapy have also been employed. ...

ByOcean Biomedical


Betaglue technologies: closing of a eur 10 million financing round

Betaglue technologies: closing of a eur 10 million financing round

This was achieved through the use of a fast-curing, biocompatible glue that effectively captures the radioactive microspheres, allowing them to be injected directly and safely into various target tissues. The latter can be either surgically unresectable tumours or metastases, which are thus irradiated in-loco, or surgical resection margins, which ...

ByBetaGlue Technologies SpA


VBI Vaccines Receives U.S. FDA Orphan Drug Designation for VBI-1901 for the Treatment of Glioblastoma

VBI Vaccines Receives U.S. FDA Orphan Drug Designation for VBI-1901 for the Treatment of Glioblastoma

” Though classified as a rare disease, GBM is the most common primary brain cancer with approximately 14,000 new cases diagnosed in the United States each year, and a low median overall survival of 15-18 months after diagnosis of primary GBM.1 Glioblastomas are stage IV brain tumors – they are an exceptionally aggressive form of brain cancer, with high recurrence rates and a ...

ByVBI Vaccines Inc.


VBI Vaccines Presents Updated Phase 2a Tumor Response and Overall Survival Data for VBI-1901 in Recurrent GBM at the 2022 ASCO Annual Meeting

VBI Vaccines Presents Updated Phase 2a Tumor Response and Overall Survival Data for VBI-1901 in Recurrent GBM at the 2022 ASCO Annual Meeting

The current standard of care for treating GBM is surgical resection, followed by radiation and chemotherapy. Even with aggressive treatment, GBM progresses rapidly and has a high mortality. ...

ByVBI Vaccines Inc.


Biostage Further Strengthens IP Portfolio with Additional Patent for Regeneration and Repair of the Bronchus

Biostage Further Strengthens IP Portfolio with Additional Patent for Regeneration and Repair of the Bronchus

Using a cell-seeded scaffold, which we call the Biostage Bronchial Implant, or BBI, we have performed the regeneration and repair of a bronchus (the airway that connects the trachea to the lungs) that was surgically removed from a pig. The bronchus regenerated, much as in the esophagus, first forming a tube and later developing into a bronchus with a functional lining known as ...

ByHarvard Apparatus Regenerative Technology, Inc. formely known as Biostage, Inc.


GeneCentric to Present Discovery and Initial Clinical Utility of a Novel RNA-Based Gene Signature That Predicts Treatment Response in Patients with Head and Neck Cancer

GeneCentric to Present Discovery and Initial Clinical Utility of a Novel RNA-Based Gene Signature That Predicts Treatment Response in Patients with Head and Neck Cancer

Oral cavity HNSCC patients with lymph node-negative disease, who are typically treated with surgical resection without additional radiation and/or chemotherapy, were identified as mesenchymal or non-mesenchymal based upon the novel RNA-based signature. ...

ByGeneCentric Therapeutics, Inc.


Edinburgh Molecular Imaging and Mauna Kea Technologies Announce Clinical Molecular Imaging Collaboration

Edinburgh Molecular Imaging and Mauna Kea Technologies Announce Clinical Molecular Imaging Collaboration

With Cellvizio and EMI-137, we will now enable for the first time highly specific real-time imaging at the cellular level in solid tumors” said Prof Go Van Dam, Professor of Surgical Oncology, and Dr Wouter Nagengast from the Optical Molecular Imaging Group (OMIG) at the University Medical Center Groningen (UMCG). ...

ByEdinburgh Molecular Imaging


Comprehensive genomic profiling-informed personalized molecular residual disease detection

Comprehensive genomic profiling-informed personalized molecular residual disease detection

Here we establish feasibility of MRD detection using Foundation Medicine’s novel tissue-informed personalized monitoring assay, FoundationOne®Tracker (F1T), in mCRC patients undergoing surgical resection with curative intent. Methods: Tissue-based CGP was performed retrospectively on a cohort of 72 patients from the PREDATOR trial. ...

ByFoundation Medicine, Inc.


SEngine Precision Medicine Announces New Collaboration to Bring PARIS Test to Patients with CNS Cancers

SEngine Precision Medicine Announces New Collaboration to Bring PARIS Test to Patients with CNS Cancers

Live tumor models from a biopsy or surgical resection of a patient’s primary or metastatic brain tumor will be generated at the Dana-Farber Center for Patient Derived Models (CPDM) using methods they have established for maximizing the viability of brain tumor cells. ...

BySEngine Precision Medicine


GT Medical Technologies Presents Clinical Data on GammaTile® Therapy for Brain Tumors at the 2021 American Association of Neurological Surgeons Scientific Virtual Meeting

GT Medical Technologies Presents Clinical Data on GammaTile® Therapy for Brain Tumors at the 2021 American Association of Neurological Surgeons Scientific Virtual Meeting

It's the first device of its kind, and its ability to deliver safe and effective Surgically Targeted Radiation Therapy (STaRT) for patients is groundbreaking in the neuro-oncology community." ...

ByGT Medical Technologies, Inc.


HistoSonics Announces Milestone as AMA Issues Unique Category III CPT Code for Histotripsy of Liver

HistoSonics Announces Milestone as AMA Issues Unique Category III CPT Code for Histotripsy of Liver

Only 20%-30% of patients with liver tumors are eligible for surgical resection due to the presence of multiple tumors, underlying poor liver function, or general health issues limiting the success of surgery. ...

ByHistoSonics


HistoSonics Announces First Patient Treated in European Clinical Trial

HistoSonics Announces First Patient Treated in European Clinical Trial

” Only 20%-30% of patients with liver tumors are eligible for surgical resection due to the presence of multiple tumors, underlying poor liver function, or general health issues limiting the success of surgery. ...

ByHistoSonics


ISET technology makes Circulating Tumor Cells accessible to target PDAC mutant genes detection in pancreatic cancer with an accuracy demonstrated by a targeted scNGS

ISET technology makes Circulating Tumor Cells accessible to target PDAC mutant genes detection in pancreatic cancer with an accuracy demonstrated by a targeted scNGS

PDAC is a devastating disease with a 5-year survival rate of less than 10%. Surgical resection of the local disease provides the greatest chance of cure, yet, approximately 80% of resected patients die with the overwhelming pattern of recurrence being systemic. Thus, understanding the mechanisms of the underlying nature of systemic disease after ...

ByRarecells Diagnostics SAS


University Hospitals Cleveland Medical Center Pilot Study Shows Promise for High-Risk Recurrent Head and Neck Cancer Treatment with Cesium-131 and Surgical Resection

University Hospitals Cleveland Medical Center Pilot Study Shows Promise for High-Risk Recurrent Head and Neck Cancer Treatment with Cesium-131 and Surgical Resection

A recently published small prospective series of patients with recurrent head and neck (H&N) cancers treated with surgical resection and Isoray’s Cesium-131 brachytherapy found potential benefits that support further research into combination therapy with Cesium-131 brachytherapy and surgical resection. ...

ByTheragenics


HistoSonics Announces First Patient Treated in US Clinical Study of Novel Sonic Beam Therapy for Liver Tumors

HistoSonics Announces First Patient Treated in US Clinical Study of Novel Sonic Beam Therapy for Liver Tumors

” Only 20%-30% of patients with liver tumors are eligible for surgical resection due to the presence of multiple tumors, underlying poor liver function, or general health issues limiting the success of surgery. ...

ByHistoSonics

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT